8.30
-0.19(-2.24%)
Currency In NaN
Address
4370 La Jolla Village Drive
San Diego, CA 92122
United States of America
Phone
858 225 7696
Sector
Healthcare
Industry
Biotechnology
Employees
22
First IPO Date
February 13, 2025
| Name | Title | Pay | Year Born |
| Dr. Tien-Li Lee M.D. | Chief Executive Officer, Secretary & Director | 703,099 | 1975 |
| Dr. Bryan Jones Ph.D. | Chief Operating Officer | 467,437 | 1964 |
| Dr. Manasi Sinha Jaiman M.D., M.P.H. | Chief Medical Officer | 503,943 | 1981 |
| Mr. Tom Bicsak Ph.D. | Head of Regulatory Affairs & Quality | 0 | N/A |
| Dr. Andreas Niethammer M.D., Ph.D. | Head of Translational Medicine | 0 | N/A |
| Mr. Nelson B. Sun M.B.A. | Chief Financial Officer | 0 | 1977 |
| Dr. Dvorit Samid Ph.D. | Executive Vice President of Medical Affairs | 0 | N/A |
| Dr. Zhenhuan Zheng Ph.D. | Chief Research Officer | 0 | N/A |
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.